The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial

Assessing the Value of Risk Predictions by Using Risk Stratification Tables

(2013) Holly Janes et al.   ANNALS OF INTERNAL MEDICINE

Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering

(2013) Mark J. Pletcher   ANNALS OF INTERNAL MEDICINE

C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force

(2013) David I. Buckley et al.   ANNALS OF INTERNAL MEDICINE

Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease

(2013) Rodney A. Hayward   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate- and Low-Cardiovascular-Risk Individuals for Statin Therapy

(2010) Keane K. Lee et al.   CIRCULATION

Should We Measure C-reactive Protein on Earth or Just on JUPITER?

(2010) Ambareesh Bajpai et al.   CLINICAL CARDIOLOGY

Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER

(2010) Julia F. Slejko et al.   CURRENT MEDICAL RESEARCH AND OPINION

Another Look at the Results of the JUPITER Trial

(2009) C. Tissa Kappagoda et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

(2009) John J.V. McMurray et al.   CIRCULATION

Criteria for Evaluation of Novel Markers of Cardiovascular Risk

(2009) Mark A. Hlatky et al.   CIRCULATION

From Here to JUPITER

(2009) Erica S. Spatz et al.  

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

(2009)  

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2009)   LANCET

Rosuvastatin in Patients with Elevated C-Reactive Protein

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander?

(2009) B.G. Nordestgaard et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study

(2008) Peter W.F. Wilson et al.  

Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts

(2008) Tina Shah et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

C-reactive protein and coronary heart disease: a critical review

(2008) J. P. Casas et al.   JOURNAL OF INTERNAL MEDICINE

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease

(2008) Jeppe Zacho et al.   NEW ENGLAND JOURNAL OF MEDICINE